Astellas Partners with Kate Therapeutics in Gene Therapy, After Four Patient Deaths in Previous Trials

Japanese pharmaceutical company Astellas Pharma has partnered with Kate Therapeutics to develop a gene therapy for X-linked myotubular myopathy (XLMTM), a rare and life-threatening neuromuscular disease leading to severe muscle weakness. The partnership aims to reduce the likelihood of severe side effects by using significantly lower doses of viral vectors responsible for delivering genes into p..